nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—Mechlorethamine—lymphatic system cancer	0.79	1	CrCtD
Cyclophosphamide—CYP3A5—Teniposide—lymphatic system cancer	0.0183	0.155	CbGbCtD
Cyclophosphamide—CYP2C19—Teniposide—lymphatic system cancer	0.0147	0.125	CbGbCtD
Cyclophosphamide—CYP2C9—Teniposide—lymphatic system cancer	0.0123	0.104	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0117	0.0995	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—lymphatic system cancer	0.0117	0.0995	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—lymphatic system cancer	0.0088	0.0747	CbGbCtD
Cyclophosphamide—ABCB1—Mitoxantrone—lymphatic system cancer	0.00832	0.0706	CbGbCtD
Cyclophosphamide—CYP3A4—Cytarabine—lymphatic system cancer	0.00724	0.0614	CbGbCtD
Cyclophosphamide—CYP3A4—Teniposide—lymphatic system cancer	0.00713	0.0605	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—lymphatic system cancer	0.00573	0.0486	CbGbCtD
Cyclophosphamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00499	0.0423	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—lymphatic system cancer	0.00347	0.0294	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—lymphatic system cancer	0.00343	0.0291	CbGbCtD
Cyclophosphamide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	6.85e-05	0.000743	CcSEcCtD
Cyclophosphamide—Ulcer—Methotrexate—lymphatic system cancer	6.85e-05	0.000743	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	6.79e-05	0.000736	CcSEcCtD
Cyclophosphamide—Decreased appetite—Fludarabine—lymphatic system cancer	6.78e-05	0.000735	CcSEcCtD
Cyclophosphamide—Visual impairment—Carmustine—lymphatic system cancer	6.77e-05	0.000734	CcSEcCtD
Cyclophosphamide—Fatigue—Fludarabine—lymphatic system cancer	6.72e-05	0.000729	CcSEcCtD
Cyclophosphamide—Inflammation—Methotrexate—lymphatic system cancer	6.68e-05	0.000724	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Vincristine—lymphatic system cancer	6.67e-05	0.000723	CcSEcCtD
Cyclophosphamide—Pain—Fludarabine—lymphatic system cancer	6.67e-05	0.000723	CcSEcCtD
Cyclophosphamide—Constipation—Fludarabine—lymphatic system cancer	6.67e-05	0.000723	CcSEcCtD
Cyclophosphamide—Bradycardia—Mitoxantrone—lymphatic system cancer	6.65e-05	0.000721	CcSEcCtD
Cyclophosphamide—Vasculitis—Methotrexate—lymphatic system cancer	6.64e-05	0.00072	CcSEcCtD
Cyclophosphamide—Respiratory failure—Methotrexate—lymphatic system cancer	6.6e-05	0.000715	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Methotrexate—lymphatic system cancer	6.6e-05	0.000715	CcSEcCtD
Cyclophosphamide—Haemoglobin—Mitoxantrone—lymphatic system cancer	6.56e-05	0.000712	CcSEcCtD
Cyclophosphamide—Rhinitis—Mitoxantrone—lymphatic system cancer	6.55e-05	0.00071	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Teniposide—lymphatic system cancer	6.54e-05	0.000709	CcSEcCtD
Cyclophosphamide—Hepatitis—Mitoxantrone—lymphatic system cancer	6.53e-05	0.000708	CcSEcCtD
Cyclophosphamide—Haemorrhage—Mitoxantrone—lymphatic system cancer	6.53e-05	0.000708	CcSEcCtD
Cyclophosphamide—Flushing—Carmustine—lymphatic system cancer	6.52e-05	0.000707	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	6.5e-05	0.000705	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Methotrexate—lymphatic system cancer	6.48e-05	0.000702	CcSEcCtD
Cyclophosphamide—Anaemia—Bleomycin—lymphatic system cancer	6.48e-05	0.000702	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Fludarabine—lymphatic system cancer	6.43e-05	0.000697	CcSEcCtD
Cyclophosphamide—Asthenia—Teniposide—lymphatic system cancer	6.37e-05	0.00069	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Methotrexate—lymphatic system cancer	6.33e-05	0.000686	CcSEcCtD
Cyclophosphamide—Malaise—Bleomycin—lymphatic system cancer	6.32e-05	0.000685	CcSEcCtD
Cyclophosphamide—Pruritus—Teniposide—lymphatic system cancer	6.28e-05	0.00068	CcSEcCtD
Cyclophosphamide—Arrhythmia—Carmustine—lymphatic system cancer	6.28e-05	0.00068	CcSEcCtD
Cyclophosphamide—Leukopenia—Bleomycin—lymphatic system cancer	6.27e-05	0.00068	CcSEcCtD
Cyclophosphamide—Cystitis—Methotrexate—lymphatic system cancer	6.26e-05	0.000678	CcSEcCtD
Cyclophosphamide—Alopecia—Carmustine—lymphatic system cancer	6.21e-05	0.000673	CcSEcCtD
Cyclophosphamide—Body temperature increased—Fludarabine—lymphatic system cancer	6.16e-05	0.000668	CcSEcCtD
Cyclophosphamide—Erythema—Carmustine—lymphatic system cancer	6.12e-05	0.000663	CcSEcCtD
Cyclophosphamide—Cough—Bleomycin—lymphatic system cancer	6.11e-05	0.000663	CcSEcCtD
Cyclophosphamide—Diarrhoea—Teniposide—lymphatic system cancer	6.07e-05	0.000658	CcSEcCtD
Cyclophosphamide—Chest pain—Bleomycin—lymphatic system cancer	5.96e-05	0.000647	CcSEcCtD
Cyclophosphamide—Myalgia—Bleomycin—lymphatic system cancer	5.96e-05	0.000647	CcSEcCtD
Cyclophosphamide—Alopecia—Vincristine—lymphatic system cancer	5.93e-05	0.000642	CcSEcCtD
Cyclophosphamide—Discomfort—Bleomycin—lymphatic system cancer	5.89e-05	0.000639	CcSEcCtD
Cyclophosphamide—Chills—Mitoxantrone—lymphatic system cancer	5.86e-05	0.000635	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Methotrexate—lymphatic system cancer	5.86e-05	0.000635	CcSEcCtD
Cyclophosphamide—Bladder pain—Methotrexate—lymphatic system cancer	5.86e-05	0.000635	CcSEcCtD
Cyclophosphamide—Neoplasm—Methotrexate—lymphatic system cancer	5.86e-05	0.000635	CcSEcCtD
Cyclophosphamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	5.83e-05	0.000632	CcSEcCtD
Cyclophosphamide—Alopecia—Mitoxantrone—lymphatic system cancer	5.77e-05	0.000626	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Methotrexate—lymphatic system cancer	5.77e-05	0.000625	CcSEcCtD
Cyclophosphamide—Confusional state—Bleomycin—lymphatic system cancer	5.77e-05	0.000625	CcSEcCtD
Cyclophosphamide—Vision blurred—Carmustine—lymphatic system cancer	5.76e-05	0.000625	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Fludarabine—lymphatic system cancer	5.75e-05	0.000623	CcSEcCtD
Cyclophosphamide—Tremor—Carmustine—lymphatic system cancer	5.73e-05	0.000621	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	5.72e-05	0.00062	CcSEcCtD
Cyclophosphamide—Oedema—Bleomycin—lymphatic system cancer	5.72e-05	0.00062	CcSEcCtD
Cyclophosphamide—Erythema—Mitoxantrone—lymphatic system cancer	5.69e-05	0.000616	CcSEcCtD
Cyclophosphamide—Infection—Bleomycin—lymphatic system cancer	5.68e-05	0.000616	CcSEcCtD
Cyclophosphamide—Anaemia—Carmustine—lymphatic system cancer	5.65e-05	0.000613	CcSEcCtD
Cyclophosphamide—Vomiting—Teniposide—lymphatic system cancer	5.64e-05	0.000612	CcSEcCtD
Cyclophosphamide—Sepsis—Methotrexate—lymphatic system cancer	5.62e-05	0.000609	CcSEcCtD
Cyclophosphamide—Agitation—Carmustine—lymphatic system cancer	5.62e-05	0.000609	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	5.6e-05	0.000607	CcSEcCtD
Cyclophosphamide—Asthenia—Fludarabine—lymphatic system cancer	5.59e-05	0.000606	CcSEcCtD
Cyclophosphamide—Rash—Teniposide—lymphatic system cancer	5.59e-05	0.000606	CcSEcCtD
Cyclophosphamide—Dermatitis—Teniposide—lymphatic system cancer	5.59e-05	0.000606	CcSEcCtD
Cyclophosphamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	5.57e-05	0.000603	CcSEcCtD
Cyclophosphamide—Headache—Teniposide—lymphatic system cancer	5.56e-05	0.000603	CcSEcCtD
Cyclophosphamide—Pruritus—Fludarabine—lymphatic system cancer	5.52e-05	0.000598	CcSEcCtD
Cyclophosphamide—Leukopenia—Carmustine—lymphatic system cancer	5.47e-05	0.000593	CcSEcCtD
Cyclophosphamide—Anorexia—Bleomycin—lymphatic system cancer	5.45e-05	0.000591	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Methotrexate—lymphatic system cancer	5.41e-05	0.000586	CcSEcCtD
Cyclophosphamide—Anaemia—Vincristine—lymphatic system cancer	5.4e-05	0.000585	CcSEcCtD
Cyclophosphamide—Agitation—Vincristine—lymphatic system cancer	5.36e-05	0.000582	CcSEcCtD
Cyclophosphamide—Vision blurred—Mitoxantrone—lymphatic system cancer	5.36e-05	0.000581	CcSEcCtD
Cyclophosphamide—Polyuria—Methotrexate—lymphatic system cancer	5.36e-05	0.000581	CcSEcCtD
Cyclophosphamide—Hypotension—Bleomycin—lymphatic system cancer	5.34e-05	0.000579	CcSEcCtD
Cyclophosphamide—Diarrhoea—Fludarabine—lymphatic system cancer	5.34e-05	0.000578	CcSEcCtD
Cyclophosphamide—Convulsion—Carmustine—lymphatic system cancer	5.3e-05	0.000574	CcSEcCtD
Cyclophosphamide—Hypertension—Carmustine—lymphatic system cancer	5.28e-05	0.000572	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	5.27e-05	0.000572	CcSEcCtD
Cyclophosphamide—Nausea—Teniposide—lymphatic system cancer	5.27e-05	0.000571	CcSEcCtD
Cyclophosphamide—Anaemia—Mitoxantrone—lymphatic system cancer	5.25e-05	0.00057	CcSEcCtD
Cyclophosphamide—Hepatic failure—Methotrexate—lymphatic system cancer	5.23e-05	0.000567	CcSEcCtD
Cyclophosphamide—Leukopenia—Vincristine—lymphatic system cancer	5.23e-05	0.000566	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	5.21e-05	0.000565	CcSEcCtD
Cyclophosphamide—Myalgia—Carmustine—lymphatic system cancer	5.21e-05	0.000564	CcSEcCtD
Cyclophosphamide—Chest pain—Carmustine—lymphatic system cancer	5.21e-05	0.000564	CcSEcCtD
Cyclophosphamide—Paraesthesia—Bleomycin—lymphatic system cancer	5.13e-05	0.000557	CcSEcCtD
Cyclophosphamide—Malaise—Mitoxantrone—lymphatic system cancer	5.13e-05	0.000556	CcSEcCtD
Cyclophosphamide—Dyspnoea—Bleomycin—lymphatic system cancer	5.1e-05	0.000553	CcSEcCtD
Cyclophosphamide—Renal failure acute—Methotrexate—lymphatic system cancer	5.09e-05	0.000552	CcSEcCtD
Cyclophosphamide—Leukopenia—Mitoxantrone—lymphatic system cancer	5.09e-05	0.000552	CcSEcCtD
Cyclophosphamide—Convulsion—Vincristine—lymphatic system cancer	5.06e-05	0.000548	CcSEcCtD
Cyclophosphamide—Hypertension—Vincristine—lymphatic system cancer	5.04e-05	0.000546	CcSEcCtD
Cyclophosphamide—Confusional state—Carmustine—lymphatic system cancer	5.03e-05	0.000545	CcSEcCtD
Cyclophosphamide—Oedema—Carmustine—lymphatic system cancer	4.99e-05	0.000541	CcSEcCtD
Cyclophosphamide—Decreased appetite—Bleomycin—lymphatic system cancer	4.97e-05	0.000539	CcSEcCtD
Cyclophosphamide—Myalgia—Vincristine—lymphatic system cancer	4.97e-05	0.000539	CcSEcCtD
Cyclophosphamide—Cough—Mitoxantrone—lymphatic system cancer	4.96e-05	0.000538	CcSEcCtD
Cyclophosphamide—Infection—Carmustine—lymphatic system cancer	4.96e-05	0.000537	CcSEcCtD
Cyclophosphamide—Vomiting—Fludarabine—lymphatic system cancer	4.96e-05	0.000537	CcSEcCtD
Cyclophosphamide—Convulsion—Mitoxantrone—lymphatic system cancer	4.93e-05	0.000534	CcSEcCtD
Cyclophosphamide—Rash—Fludarabine—lymphatic system cancer	4.92e-05	0.000533	CcSEcCtD
Cyclophosphamide—Dermatitis—Fludarabine—lymphatic system cancer	4.91e-05	0.000532	CcSEcCtD
Cyclophosphamide—Hypertension—Mitoxantrone—lymphatic system cancer	4.91e-05	0.000532	CcSEcCtD
Cyclophosphamide—Pain—Bleomycin—lymphatic system cancer	4.89e-05	0.00053	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Carmustine—lymphatic system cancer	4.89e-05	0.00053	CcSEcCtD
Cyclophosphamide—Headache—Fludarabine—lymphatic system cancer	4.89e-05	0.00053	CcSEcCtD
Cyclophosphamide—Tachycardia—Carmustine—lymphatic system cancer	4.87e-05	0.000528	CcSEcCtD
Cyclophosphamide—Chest pain—Mitoxantrone—lymphatic system cancer	4.84e-05	0.000525	CcSEcCtD
Cyclophosphamide—Arthralgia—Mitoxantrone—lymphatic system cancer	4.84e-05	0.000525	CcSEcCtD
Cyclophosphamide—Myalgia—Mitoxantrone—lymphatic system cancer	4.84e-05	0.000525	CcSEcCtD
Cyclophosphamide—Discomfort—Mitoxantrone—lymphatic system cancer	4.78e-05	0.000518	CcSEcCtD
Cyclophosphamide—Oedema—Vincristine—lymphatic system cancer	4.76e-05	0.000516	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Vincristine—lymphatic system cancer	4.76e-05	0.000516	CcSEcCtD
Cyclophosphamide—Anorexia—Carmustine—lymphatic system cancer	4.76e-05	0.000516	CcSEcCtD
Cyclophosphamide—Infection—Vincristine—lymphatic system cancer	4.73e-05	0.000513	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Bleomycin—lymphatic system cancer	4.71e-05	0.000511	CcSEcCtD
Cyclophosphamide—Confusional state—Mitoxantrone—lymphatic system cancer	4.68e-05	0.000507	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Vincristine—lymphatic system cancer	4.66e-05	0.000506	CcSEcCtD
Cyclophosphamide—Hypotension—Carmustine—lymphatic system cancer	4.66e-05	0.000506	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	4.64e-05	0.000503	CcSEcCtD
Cyclophosphamide—Oedema—Mitoxantrone—lymphatic system cancer	4.64e-05	0.000503	CcSEcCtD
Cyclophosphamide—Nausea—Fludarabine—lymphatic system cancer	4.63e-05	0.000502	CcSEcCtD
Cyclophosphamide—Infection—Mitoxantrone—lymphatic system cancer	4.61e-05	0.0005	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Vincristine—lymphatic system cancer	4.61e-05	0.000499	CcSEcCtD
Cyclophosphamide—Shock—Mitoxantrone—lymphatic system cancer	4.56e-05	0.000495	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	4.55e-05	0.000493	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	4.54e-05	0.000492	CcSEcCtD
Cyclophosphamide—Urticaria—Bleomycin—lymphatic system cancer	4.54e-05	0.000492	CcSEcCtD
Cyclophosphamide—Anorexia—Vincristine—lymphatic system cancer	4.54e-05	0.000492	CcSEcCtD
Cyclophosphamide—Tachycardia—Mitoxantrone—lymphatic system cancer	4.53e-05	0.000491	CcSEcCtD
Cyclophosphamide—Body temperature increased—Bleomycin—lymphatic system cancer	4.52e-05	0.00049	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	4.49e-05	0.000486	CcSEcCtD
Cyclophosphamide—Paraesthesia—Carmustine—lymphatic system cancer	4.48e-05	0.000486	CcSEcCtD
Cyclophosphamide—Hypotension—Vincristine—lymphatic system cancer	4.45e-05	0.000483	CcSEcCtD
Cyclophosphamide—Dyspnoea—Carmustine—lymphatic system cancer	4.45e-05	0.000482	CcSEcCtD
Cyclophosphamide—Anorexia—Mitoxantrone—lymphatic system cancer	4.42e-05	0.000479	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	4.34e-05	0.000471	CcSEcCtD
Cyclophosphamide—Decreased appetite—Carmustine—lymphatic system cancer	4.34e-05	0.00047	CcSEcCtD
Cyclophosphamide—Hypotension—Mitoxantrone—lymphatic system cancer	4.34e-05	0.00047	CcSEcCtD
Cyclophosphamide—Paraesthesia—Vincristine—lymphatic system cancer	4.28e-05	0.000464	CcSEcCtD
Cyclophosphamide—Pain—Carmustine—lymphatic system cancer	4.27e-05	0.000463	CcSEcCtD
Cyclophosphamide—Constipation—Carmustine—lymphatic system cancer	4.27e-05	0.000463	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	4.24e-05	0.000459	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	4.23e-05	0.000458	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Bleomycin—lymphatic system cancer	4.21e-05	0.000457	CcSEcCtD
Cyclophosphamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	4.17e-05	0.000452	CcSEcCtD
Cyclophosphamide—Decreased appetite—Vincristine—lymphatic system cancer	4.14e-05	0.000449	CcSEcCtD
Cyclophosphamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	4.14e-05	0.000448	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Carmustine—lymphatic system cancer	4.11e-05	0.000446	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—lymphatic system cancer	4.11e-05	0.000445	CcSEcCtD
Cyclophosphamide—Asthenia—Bleomycin—lymphatic system cancer	4.1e-05	0.000445	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—lymphatic system cancer	4.07e-05	0.000442	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—lymphatic system cancer	4.07e-05	0.000442	CcSEcCtD
Cyclophosphamide—Pruritus—Bleomycin—lymphatic system cancer	4.05e-05	0.000438	CcSEcCtD
Cyclophosphamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	4.03e-05	0.000437	CcSEcCtD
Cyclophosphamide—Fatigue—Mitoxantrone—lymphatic system cancer	4e-05	0.000434	CcSEcCtD
Cyclophosphamide—Pain—Mitoxantrone—lymphatic system cancer	3.97e-05	0.00043	CcSEcCtD
Cyclophosphamide—Constipation—Mitoxantrone—lymphatic system cancer	3.97e-05	0.00043	CcSEcCtD
Cyclophosphamide—Body temperature increased—Carmustine—lymphatic system cancer	3.95e-05	0.000428	CcSEcCtD
Cyclophosphamide—Abdominal discomfort—Methotrexate—lymphatic system cancer	3.9e-05	0.000422	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—lymphatic system cancer	3.86e-05	0.000418	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	3.82e-05	0.000414	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—lymphatic system cancer	3.77e-05	0.000408	CcSEcCtD
Cyclophosphamide—Urticaria—Mitoxantrone—lymphatic system cancer	3.69e-05	0.0004	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Carmustine—lymphatic system cancer	3.68e-05	0.000399	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000398	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—lymphatic system cancer	3.65e-05	0.000395	CcSEcCtD
Cyclophosphamide—Vomiting—Bleomycin—lymphatic system cancer	3.64e-05	0.000394	CcSEcCtD
Cyclophosphamide—Rash—Bleomycin—lymphatic system cancer	3.61e-05	0.000391	CcSEcCtD
Cyclophosphamide—Dermatitis—Bleomycin—lymphatic system cancer	3.6e-05	0.00039	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	3.59e-05	0.00039	CcSEcCtD
Cyclophosphamide—Asthenia—Carmustine—lymphatic system cancer	3.58e-05	0.000388	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—lymphatic system cancer	3.56e-05	0.000386	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—lymphatic system cancer	3.53e-05	0.000383	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—lymphatic system cancer	3.52e-05	0.000382	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—lymphatic system cancer	3.51e-05	0.00038	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—lymphatic system cancer	3.47e-05	0.000377	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—lymphatic system cancer	3.46e-05	0.000375	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	3.42e-05	0.000371	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—lymphatic system cancer	3.42e-05	0.000371	CcSEcCtD
Cyclophosphamide—Diarrhoea—Carmustine—lymphatic system cancer	3.41e-05	0.00037	CcSEcCtD
Cyclophosphamide—Nausea—Bleomycin—lymphatic system cancer	3.4e-05	0.000368	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—lymphatic system cancer	3.38e-05	0.000367	CcSEcCtD
Cyclophosphamide—Asthenia—Mitoxantrone—lymphatic system cancer	3.33e-05	0.000361	CcSEcCtD
Cyclophosphamide—Dizziness—Carmustine—lymphatic system cancer	3.3e-05	0.000358	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—lymphatic system cancer	3.27e-05	0.000354	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—lymphatic system cancer	3.26e-05	0.000353	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—lymphatic system cancer	3.25e-05	0.000353	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—lymphatic system cancer	3.25e-05	0.000353	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	3.17e-05	0.000344	CcSEcCtD
Cyclophosphamide—Vomiting—Carmustine—lymphatic system cancer	3.17e-05	0.000344	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—lymphatic system cancer	3.15e-05	0.000342	CcSEcCtD
Cyclophosphamide—Rash—Carmustine—lymphatic system cancer	3.15e-05	0.000341	CcSEcCtD
Cyclophosphamide—Dermatitis—Carmustine—lymphatic system cancer	3.14e-05	0.000341	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—lymphatic system cancer	3.14e-05	0.00034	CcSEcCtD
Cyclophosphamide—Headache—Carmustine—lymphatic system cancer	3.13e-05	0.000339	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—lymphatic system cancer	3.08e-05	0.000333	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—lymphatic system cancer	3.03e-05	0.000329	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—lymphatic system cancer	3.03e-05	0.000328	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—lymphatic system cancer	3e-05	0.000326	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—lymphatic system cancer	3e-05	0.000325	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—lymphatic system cancer	2.98e-05	0.000324	CcSEcCtD
Cyclophosphamide—Nausea—Carmustine—lymphatic system cancer	2.96e-05	0.000321	CcSEcCtD
Cyclophosphamide—Vomiting—Mitoxantrone—lymphatic system cancer	2.95e-05	0.00032	CcSEcCtD
Cyclophosphamide—Rash—Mitoxantrone—lymphatic system cancer	2.93e-05	0.000317	CcSEcCtD
Cyclophosphamide—Dermatitis—Mitoxantrone—lymphatic system cancer	2.92e-05	0.000317	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—lymphatic system cancer	2.92e-05	0.000316	CcSEcCtD
Cyclophosphamide—Headache—Mitoxantrone—lymphatic system cancer	2.91e-05	0.000315	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—lymphatic system cancer	2.88e-05	0.000312	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—lymphatic system cancer	2.83e-05	0.000307	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—lymphatic system cancer	2.83e-05	0.000307	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—lymphatic system cancer	2.77e-05	0.000301	CcSEcCtD
Cyclophosphamide—Nausea—Mitoxantrone—lymphatic system cancer	2.76e-05	0.000299	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—lymphatic system cancer	2.67e-05	0.000289	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.63e-05	0.000285	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—lymphatic system cancer	2.62e-05	0.000284	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—lymphatic system cancer	2.55e-05	0.000277	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—lymphatic system cancer	2.54e-05	0.000275	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—lymphatic system cancer	2.47e-05	0.000268	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—lymphatic system cancer	2.45e-05	0.000266	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—lymphatic system cancer	2.41e-05	0.000261	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—lymphatic system cancer	2.41e-05	0.000261	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—lymphatic system cancer	2.41e-05	0.000261	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—lymphatic system cancer	2.38e-05	0.000258	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—lymphatic system cancer	2.33e-05	0.000253	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	2.31e-05	0.000251	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—lymphatic system cancer	2.3e-05	0.000249	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.26e-05	0.000245	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.23e-05	0.000242	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—lymphatic system cancer	2.2e-05	0.000239	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—lymphatic system cancer	2.16e-05	0.000234	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.11e-05	0.000228	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—lymphatic system cancer	2.08e-05	0.000225	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—lymphatic system cancer	2.06e-05	0.000223	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—lymphatic system cancer	2.01e-05	0.000218	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—lymphatic system cancer	1.99e-05	0.000216	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—lymphatic system cancer	1.98e-05	0.000214	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—lymphatic system cancer	1.9e-05	0.000206	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—lymphatic system cancer	1.84e-05	0.000199	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—lymphatic system cancer	1.83e-05	0.000198	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—lymphatic system cancer	1.7e-05	0.000185	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—lymphatic system cancer	1.66e-05	0.00018	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—lymphatic system cancer	1.64e-05	0.000177	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—lymphatic system cancer	1.58e-05	0.000171	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—lymphatic system cancer	1.53e-05	0.000166	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—lymphatic system cancer	1.47e-05	0.000159	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—lymphatic system cancer	1.46e-05	0.000158	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—lymphatic system cancer	1.46e-05	0.000158	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—lymphatic system cancer	1.45e-05	0.000157	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—lymphatic system cancer	1.37e-05	0.000149	CcSEcCtD
